R3421: Phase II started

BioCryst began a 2-part, double-blind, placebo-controlled, dose-ranging, U.S. Phase II trial to evaluate oral BCX-4208 in up to 120 patients. The first portion will evaluate 40, 80 and 120 mg of BCX4...